The document is a report on top business models in the life sciences sector from Tracxn. It provides an overview of funding in life sciences in the past year, top funded business models, and recent funding rounds for some of the top business models. The top 4 funded business models were cancer drugs ($1.9B), cancer diagnostic tests ($1.3B), cheminformatics for drug discovery ($1.2B), and high-throughput DNA sequencing instruments ($1.2B). It provides details on funding amounts, number of rounds, and examples for each business model.

1. TRACXN TOP BUSINESS MODELS REPORT
February 17, 2021
LIFE SCIENCES

2. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Contents
Life Sciences Funding - Overview 3
Top Funded Business Models 4
One pagers 9
Appendix 59
2

3. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Funding in last 1 year
3
Oncology $17.8B
Genomics $13.2B
Biotech R&D $10.5B
Immunotherapy $9.2B
Diagnostics (by Technology) $5.9B
Neurology $3.7B
Y-o-Y Funding
Top Investors by Funding Rounds
Seed
Stage
Y Combinator
Illumina
Khosla Ventures
16
6
4
Early
Stage
Casdin Capital
Orbimed
GV
26
21
19
Late
Stage
Orbimed
RA Capital Management
Janus Henderson Investors
30
25
17
Funding by Geography
Top Feeds by $ Funding
Top Funding Rounds
United States (67%)
China (16%)
United Kingdom (3%)
Germany (2%)
Israel (2%)
Switzerland (2%)
Canada (1%)
Others (6%)
$ Funding # Rounds
MGI
(2016, China)
$1.0B - Series B
Sana Biotechnology
(2018, United States)
$821M - Series D
Lyell Immunopharma
(2018, United States)
$493M - Series C
GRAIL
(2016, United States)
$390M - Series D
Indigo
(2016, United States)
$360M - Series F
CureVac
(2000, Germany)
$343M - Series F
XtalPi
(2014, United States)
$319M - Series C
LianBio
(1999, China)
$310M - Series D
Tizona Therapeutics
(2015, United States)
$300M - Series D
Zymergen
(2013, United States)
$300M - Series D
Pionyr Immuntherapeutics
(2015, United States)
$275M - Series C
Freenome
(2014, United States)
$270M - Series C

4. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (1/5)
4
Rank Business Model $ Funding # Rounds Top Funding Round Details
1<> 0 Cancer Drugs $1.9B 48 Lyell Immunop.. | $493M | Series C Link
2▲3 Cancer Diagnostic Tests $1.3B 21 GRAIL | $390M | Series D Link
3▲9 Cheminformatics for Drug Discovery $1.2B 18 XtalPi | $319M | Series C Link
4<> 0 High-Throughput DNA Sequencing Instruments $1.2B 3 MGI | $1.0B | Series B Link
5▲11
Clinical Genomics > Sequencing Based > Liquid
Biopsy > DNA
$942M 13 GRAIL | $390M | Series D Link
6▲171 Ophthalmology > Drugs > Retinal Disorders $895M 17 CureVac | $343M | Series F Link
7▲384 Cell Therapy > Somatic Cells $833M 4 Sana Biotechn.. | $821M | Series D Link
8▲11 Gene Editing Platforms $792M 15 Tessera Thera.. | $230M | Series B Link
9▼7
Clinical Genomics > Sequencing Based > Precision
Medicine
$759M 29 Caris Lif.. | $235M | Unattributed Link
10▲12 Inflammatory Diseases Drugs $703M 26 Flame Bioscie.. | $100M | Series B Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

5. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (2/5)
5
Rank Business Model $ Funding # Rounds Top Funding Round Details
11▼5 Neurodegenerative Disorders Drugs $650M 35 Annexon | $102M | Series D Link
12▼5 Genomic Biomarker Discovery Research $640M 9 Freenome | $270M | Series C Link
13<> 0 Antibody Engineering Platforms $618M 15 Lepu Biotechn.. | $186M | Series B Link
14▲101 Antibacterial Drugs $615M 31 Everest Medic.. | $260M | Series C Link
15▲94 Immunology > Drugs > Autoimmune Diseases $606M 15 D3 Bio | $200M | Series A Link
16▼13 Biologics based Drug Discovery $512M 23 Ruike | $100M | Series B Link
17▲19
Infectious Diseases > Drugs > Bacterial > Drug
Resistant Infections
$504M 17 Everest Medic.. | $260M | Series C Link
18▲128 Proteomic Based Diagnostic Tests $478M 8 Somalogic | $212M | Series E Link
19▲417 Gene Therapy > Diversified $469M 10 AAVANTIBio | $107M | Series A Link
20▲434 Oncology > Drugs > Breast Cancer $449M 6 Beijing Mabwo.. | $160M | Series C Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

6. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (3/5)
6
Rank Business Model $ Funding # Rounds Top Funding Round Details
21▲2 At-Home Preventive Genetic Test Kits $430M 6 Everly Wellness | $175M | Series D Link
22▲129 Biotech R&D > Research Applications > Proteomics $424M 9 Somalogic | $212M | Series E Link
23▼5 Hematologic Cancer Drugs $390M 8 Orca Bio | $192M | Series D Link
24▲111 Precision Medicine Software $386M 6 3DMed | $224M | Series D Link
25▲29
Biotech R&D > Research Applications > Genomics >
Genome Engineering > Gene Editing
$371M 13 Tessera Thera.. | $230M | Series B Link
26▲9 Heart Failure Therapy Devices $366M 16 Element Science | $146M | Series C Link
27▲12
Biotech R&D > Research Applications > Translational
Research > Biomarkers > Agriculture
$360M 1 Indigo | $360M | Series F Link
28▼4 Immunotherapy > Oncolytic Virus $344M 10 Adlai Nortye | $100M | Series C Link
29▼18 Robotic Surgery Instruments $337M 13 Edge Medical.. | $92.6M | Series B Link
30▲10 Rare Neurological Disease Drugs $336M 8 Neurogene | $115M | Series B Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

7. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (4/5)
7
Rank Business Model $ Funding # Rounds Top Funding Round Details
31▼22 Rare Metabolic Disorder Drugs $328M 19 Goldfinch | $100M | Series B Link
32▲30 Immunology > Drugs > GvHD $322M 3 Orca Bio | $192M | Series D Link
33▼6 Neurology > Drugs > Neuromuscular $319M 11 Dyne Therapeu.. | $116M | Series B Link
34▼26 Diabetes Drugs $319M 19 Kriya Therap.. | $85.6M | Series A Link
35▲53 Cell Therapy > Diversified $315M 8 Orca Bio | $192M | Series D Link
36--
Cardiac and Vascular Disorders > Drugs > Valvular
Disorders
$310M 1 LianBio | $310M | Series D Link
37▼27 Synthetic Biology $307M 7 Pivot Bio | $100M | Series C Link
38▲31
Diagnostics (by Technology) > Diagnostic Assays and
Systems > In vitro Diagnostics > Cell or ..
$284M 3 Thrive Earlie.. | $257M | Series B Link
39▲477 Genomics Research Services $284M 13 Genechem | $56.4M | Series C Link
40▲19
Small Molecules Targeting Immunosuppressive
Pathway Inhibitors
$273M 6 iTeos Therape.. | $125M | Series B Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

8. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (5/5)
8
Rank Business Model $ Funding # Rounds Top Funding Round Details
41▼11
Diagnostics (by Technology) > Diagnostic Assays and
Systems > In vitro Diagnostics > Multi-om..
$270M 2 Freenome | $270M | Series C Link
42▲43 Genetic Engineering Technologies $265M 8 Senti Bioscie.. | $105M | Series B Link
43▲154
Biotech R&D > Research Software >
Chemoinformatics
$254M 8 Frontier Med.. | $67.0M | Series A Link
44▲123
Life Sciences Tech > Research & Development >
Image Analysis > Digital Pathology
$252M 7 PAIGE | $100M | Series C Link
45▲129 Genomics > Genomics Services > Full Service $249M 9 Huayin Health | $85.0M | Series C Link
46▲336 Pharmocogenomic Tests $249M 5 Caris Lif.. | $235M | Unattributed Link
47▲128 Spinal Therapy Devices $246M 18 Relievant Me.. | $70.0M | Series F Link
48▼23 siRNA based Gene Therapy Drugs $243M 5 Sirnaomics | $105M | Series D Link
49--
Gastroenterology > Drugs > Bowel Disorders >
Inflammatory Bowel Disorders
$241M 7 Prometheus Bi.. | $130M | Series D Link
50-- Rare Diseases > Drugs > Autoimmune Diseases $240M 3 Annexon | $102M | Series D Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

9. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Lyell Immunop.. (2018, United States)
$493M - Series C - Mar 2020
VelosBio (2017, United States)
$137M - Series B - Jul 2020
TScan Therape.. (1995, United States)
$100M - Series C - Jan 2021
Gracell Bio (2017, China)
$100M - Series C - Oct 2020
Bolt Biothera.. (2015, United States)
$93.5M - Series C - Jul 2020
Wuhan Binhui Biotechn.. (2010, China)
$92.9M - Series B - Feb 2021
Shattuck Labs (2016, United States)
$83.0M - Series C - Jun 2020
View all 48 Funding Rounds on Tracxn Platform
Cancer Drugs
01
9
Back to index
Oncology (Adaptive Biotechnologies)
(# Cos: 3962 | $79.7B)
Drugs (BioNTech)
(# Cos: 2543 | $61.1B)
Pan Cancer (GigaGen)
(# Cos: 345 | $6.9B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$1.9B (▲61.6%)
48(▼9.4%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
23
$6.9B
221
39
345
43
GigaGen
(2011, United States, $36.1M)
TScan Therapeutics
(1995, United States, $180M)
Fusion Pharmaceuticals
(2014, Canada, $171M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

10. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
GRAIL (2016, United States)
$390M - Series D - May 2020
Freenome (2014, United States)
$270M - Series C - Aug 2020
Color (2013, United States)
$167M - Series D - Jan 2021
Genecast (2016, China)
$149M - Series E - Oct 2020
Personal Genome (2010, United States)
$103M - Series C - Feb 2021
NovellusDx (2011, Israel)
$57.0M - Series C - Sep 2020
Earli (2018, United States)
$40.0M - Series A - Jan 2021
View all 21 Funding Rounds on Tracxn Platform
Cancer Diagnostic Tests
02
10
Back to index
Oncology (BioNTech)
(# Cos: 3962 | $79.7B)
In-Vitro Diagnostic Tests (Adaptive
Biotechnologies)
(# Cos: 1020 | $14.7B)
Pan Cancer (Guardant Health)
(# Cos: 192 | $5.8B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$1.3B (▲171%)
21(▼8.7%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
21
$5.8B
125
10
192
20
Guardant Health
(2012, United States, $558M)
GRAIL
(2016, United States, $2.0B)
Color
(2013, United States, $391M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

11. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Cheminformatics for Drug Discovery
03
11
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$1.2B (▲220%)
18(▲12.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
18
$2.6B
110
6
217
15
Life Sciences Tech (Veeva Systems)
(# Cos: 3282 | $14.6B)
Research & Development (Medidata)
(# Cos: 2538 | $11.7B)
Drug Discovery (Illumina)
(# Cos: 752 | $6.7B)
Cheminformatics (Atomwise)
(# Cos: 217 | $2.6B)
Atomwise
(2012, United States, $175M)
Recursion
(2013, United States, $455M)
Schrodinger
(1990, United States, $162M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
XtalPi (2014, United States)
$319M - Series C - Sep 2020
Recursion (2013, United States)
$246M - Series D - Nov 2020
ValoHealth (2019, United States)
$190M - Series B - Jan 2021
ATAI (2018, Germany)
$125M - Series C - Nov 2020
Atomwise (2012, United States)
$123M - Series B - Aug 2020
Exscientia (2012, United Kingdom)
$60.0M - Series C - May 2020
Genesis Thera.. (2019, United States)
$52.0M - Series A - Dec 2020
View all 18 Funding Rounds on Tracxn Platform

12. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
High-Throughput DNA Sequencing
Instruments
04
12
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$1.2B (▲133%)
3(▼62.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
13
$3.7B
32
3
44
6
Biotech R&D (Thermo Fisher Scientific)
(# Cos: 10357 | $53.7B)
Instrument Systems (10X Genomics)
(# Cos: 1794 | $9.0B)
DNA Sequencing Platforms (Nanopore)
(# Cos: 57 | $3.7B)
HT Sequencing Platforms
(Illumina)
(# Cos: 44 | $3.7B)
Illumina
(1998, United States, $28.0M)
Nanopore
(2005, United Kingdom, $991M)
GenapSys
(2010, United States, $243M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
MGI (2016, China)
$1.0B - Series B - Apr 2020
Nanopore (2005, United Kingdom)
$110M - Series G - Oct 2020
Nanopore (2005, United Kingdom)
$60.0M - Series G - May 2020

13. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Clinical Genomics > Sequencing Based >
Liquid Biopsy > DNA
05
13
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$942M (▲247%)
13( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
7
$4.0B
54
5
87
11
Clinical Genomics (MyHeritage)
(# Cos: 1568 | $24.7B)
Sequencing Based (Illumina)
(# Cos: 1324 | $23.1B)
Liquid Biopsy (GRAIL)
(# Cos: 151 | $4.6B)
DNA (Guardant Health)
(# Cos: 87 | $4.0B)
Guardant Health
(2012, United States, $558M)
GRAIL
(2016, United States, $2.0B)
Epigenomics
(1998, Germany, $46.7M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
GRAIL (2016, United States)
$390M - Series D - May 2020
Thrive Earlie.. (2019, United States)
$257M - Series B - Jul 2020
Genecast (2016, China)
$149M - Series E - Oct 2020
Jiyinga Technology (2015, China)
$38.0M - Series B - Nov 2020
Inivata (2014, United Kingdom)
$35.0M - Series C - Feb 2021
Inivata (2014, United Kingdom)
$25.0M - Series C - Jun 2020
Naveris (2017, United States)
$17.0M - Series B - Mar 2020
View all 13 Funding Rounds on Tracxn Platform

14. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
CureVac (2000, Germany)
$343M - Series F - Jun 2020
CureVac (2000, Germany)
$171M - Series F - Jul 2020
CureVac (2000, Germany)
$126M - Series F - Jul 2020
Wuhan Newfoss Biotech.. (2008, China)
$62.0M - Series B - Feb 2021
Stargazer Pha.. (2020, United States)
$57.0M - Series A - Nov 2020
Atsena Therap.. (2020, United States)
$55.0M - Series A - Dec 2020
Kanaph (2019, South Korea)
$21.0M - Series B - Oct 2020
View all 17 Funding Rounds on Tracxn Platform
Ophthalmology > Drugs > Retinal
Disorders
06
14
Back to index
Ophthalmology (Zeiss)
(# Cos: 897 | $10.4B)
Drugs (Adverum Biotechnologies)
(# Cos: 277 | $5.7B)
Retinal Disorders (CureVac)
(# Cos: 47 | $1.5B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$895M (▲1934%)
17(▲183%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$1.5B
31
7
47
6
CureVac
(2000, Germany, $975M)
Rezolute
(2012, United States)
Molecular Partners
(2004, Switzerland, $59.9M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

15. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Cell Therapy > Somatic Cells
07
15
Back to index
Cell Therapy (Kite Pharma)
(# Cos: 539 | $13.2B)
Somatic Cells (Enlivex Pharmaceuticals)
(# Cos: 50 | $1.6B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$833M (▲8225%)
4(▲33.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
4
$1.6B
41
14
50
2
Enlivex Pharmaceuticals
(2005, Israel, $15.0M)
Sana Biotechnology
(2018, United States, $821M)
Nuo Therapeutics
(2001, United States, $64.6M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Sana Biotechn.. (2018, United States)
$821M - Series D - Jun 2020
Endogena Therap.. (2014, Switzerland)
$8.0M - Series A - Jan 2021
LyGenesis (2017, United States)
$1.9M - Series B - Dec 2020
Koligo Therap.. (2016, United States)
$1.6M - Seed - Oct 2020

16. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Gene Editing Platforms
08
16
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$792M (▲217%)
15(▼6.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
5
$1.4B
51
2
80
13
Genomics (Illumina)
(# Cos: 6712 | $69.7B)
Enabling Technologies (10X Genomics)
(# Cos: 1535 | $16.0B)
Technology Platforms (Kite Pharma)
(# Cos: 338 | $8.3B)
Gene Editing (Horizon Discovery)
(# Cos: 80 | $1.4B)
Horizon Discovery
(2007, United Kingdom, $46.3M)
Locus Biosciences
(2015, United States, $32.3M)
Vineti
(2016, United States, $151M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Tessera Thera.. (2018, United States)
$230M - Series B - Jan 2021
Locana (2016, United States)
$100M - Series B - Dec 2020
Korro Bio (2018, United States)
$91.5M - Series A - Sep 2020
Remix Therape.. (2019, United States)
$81.0M - Series A - Dec 2020
Vineti (2016, United States)
$68.4M - Series C - Oct 2020
EdiGene (2015, China)
$67.0M - Series B - Oct 2020
Graphite Bio (2020, United States)
$45.0M - Series A - Sep 2020
View all 15 Funding Rounds on Tracxn Platform

17. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Caris Life Sc.. (1996, United States)
$235M - Unattributed - Oct 2020
Ambrx (2003, United States)
$200M - Series E - Nov 2020
Poseida Thera.. (2015, United States)
$110M - Series D - Jun 2020
Omega (2016, United States)
$85.0M - Series B - Jul 2020
Congenica (2013, United Kingdom)
$50.0M - Series C - Nov 2020
Repare Therapeutics (2016, Canada)
$15.0M - Series B - May 2020
Base Genomics (2019, United Kingdom)
$11.0M - Seed - Jun 2020
View all 29 Funding Rounds on Tracxn Platform
Clinical Genomics > Sequencing Based >
Precision Medicine
09
17
Back to index
Clinical Genomics (MyHeritage)
(# Cos: 1568 | $24.7B)
Sequencing Based (Illumina)
(# Cos: 1324 | $23.1B)
Precision Medicine (MiRagen)
(# Cos: 343 | $10.4B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$759M (▼17.8%)
29(▼14.7%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
30
$10.4B
175
46
343
25
MiRagen
(2007, United States, $43.6M)
Bluebird Bio
(1992, United States, $136M)
Juno Therapeutics
(2013, United States, $317M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

18. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Flame Bioscie.. (2019, United States)
$100M - Series B - Sep 2020
Vera Therapeu.. (2016, United States)
$80.0M - Series C - Jan 2021
Escient Pharm.. (2017, United States)
$77.5M - Series B - Sep 2020
NodThera (2016, United Kingdom)
$55.0M - Series B - Jun 2020
Immune Regul.. (2011, United Kingdom)
$52.4M - Series B - Sep 2020
Be Bio (2020, United States)
$52.0M - Series A - Oct 2020
Nereid (1999, United States)
$50.0M - Series A - Nov 2020
View all 26 Funding Rounds on Tracxn Platform
Inflammatory Diseases Drugs
10
18
Back to index
Immunology (DBV Technologies)
(# Cos: 744 | $16.6B)
Drugs (Moderna)
(# Cos: 620 | $15.8B)
Inflammatory Diseases (RedHill
Biopharma)
(# Cos: 204 | $3.1B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$703M (▲194%)
26(▲44.4%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
22
$3.1B
146
19
204
23
RedHill Biopharma
(2009, Israel, $13.5M)
Gossamer Bio
(2017, United States, $330M)
Inflazome
(2016, Ireland, $65.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

19. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Annexon (2011, United States)
$102M - Series D - Jul 2020
Athira Pharma (2011, United States)
$89.0M - Series B - Jun 2020
LEXEO Therape.. (2018, United States)
$85.0M - Series A - Jan 2021
Pipeline Ther.. (2017, United States)
$80.0M - Series C - Feb 2021
Autobahn Ther.. (2019, United States)
$76.0M - Series B - Jun 2020
ESCAPE Bio (2015, United States)
$73.0M - Series C - Sep 2020
Aspen Neurosc.. (2018, United States)
$70.0M - Series A - Apr 2020
View all 35 Funding Rounds on Tracxn Platform
Neurodegenerative Disorders Drugs
11
19
Back to index
Neurology (Kernel)
(# Cos: 2170 | $24.9B)
Drugs (Zogenix)
(# Cos: 1169 | $18.9B)
Neurodegenerative (Biogen)
(# Cos: 436 | $6.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$650M (▲34.5%)
35(▲2.9%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
29
$6.3B
295
45
436
40
Biogen
(1978, United States, $80.0M)
Yumanity Therapeutics
(2014, United States, $51.0M)
Athira Pharma
(2011, United States, $109M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

20. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Freenome (2014, United States)
$270M - Series C - Aug 2020
Goldfinch (2016, United States)
$100M - Series B - Jun 2020
Denovo Biopha.. (2013, United States)
$83.3M - Series C - Jun 2020
Tango Therape.. (2017, United States)
$60.0M - Series B - Apr 2020
Tango Therape.. (2017, United States)
$50.0M - Series B - Aug 2020
Denovo Biopha.. (2013, United States)
$45.9M - Series D - Dec 2020
Metabolon (2000, United States)
$21.8M - Series G - Sep 2020
View all 9 Funding Rounds on Tracxn Platform
Genomic Biomarker Discovery Research
12
20
Back to index
Genomics (Illumina)
(# Cos: 6712 | $69.7B)
Genomics Research (eGenesis Bio)
(# Cos: 161 | $3.3B)
Biomarker Discovery (Freenome)
(# Cos: 73 | $2.4B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$640M (▲32.6%)
9(▲12.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
7
$2.4B
43
5
73
10
Freenome
(2014, United States, $508M)
Metabolon
(2000, United States, $148M)
Lexicon Pharmaceuticals
(1995, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

21. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Antibody Engineering Platforms
13
21
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$618M (▲64%)
15(▲36.4%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
12
$1.3B
83
6
160
9
Biotech R&D (Illumina)
(# Cos: 10357 | $53.7B)
Research Applications (Horizon Discovery)
(# Cos: 3784 | $31.4B)
Protein Technology (Sutro Biopharma)
(# Cos: 327 | $2.7B)
Antibody Engineering (AbCellera)
(# Cos: 160 | $1.3B)
AbCellera
(2012, Canada, $115M)
ImmunoPrecise Antibodies
(1989, Canada)
ADC Biotechnology
(2010, United Kingdom, $16.2M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Lepu Biotechnology (2018, China)
$186M - Series B - Aug 2020
AbCellera (2012, Canada)
$105M - Series B - May 2020
Transcenta (2019, China)
$105M - Series C - Dec 2020
Wuhan Binhui Biotechn.. (2010, China)
$92.9M - Series B - Feb 2021
Dren Bio (2019, United States)
$60.0M - Series A - Sep 2020
Hinge Bio (2015, United States)
$18.2M - Series B - Apr 2020
Hinge Bio (2015, United States)
$18.0M - Series B - Feb 2021
View all 15 Funding Rounds on Tracxn Platform

22. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Everest Medic.. (2017, United States)
$260M - Series C - Jun 2020
Affinivax (2013, United States)
$226M - Series C - Jan 2021
Affinivax (2013, United States)
$120M - Series B - Apr 2020
SutroVax (2013, United States)
$110M - Series D - Apr 2020
MicuRx Pharma.. (2007, United States)
$107M - Series E - Dec 2020
Minervax (2010, Denmark)
$57.4M - Series B - Dec 2020
Everest Medic.. (2017, United States)
$50.0M - Series C - Mar 2020
View all 31 Funding Rounds on Tracxn Platform
Antibacterial Drugs
14
22
Back to index
Infectious Diseases (Oxford Immunotec)
(# Cos: 1690 | $23.1B)
Drugs (Moderna)
(# Cos: 950 | $18.9B)
Bacterial (Paratek Pharma)
(# Cos: 320 | $5.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$615M (▲706%)
31(▲3.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
34
$5.3B
238
37
320
33
Paratek Pharma
(1996, United States, $96.5M)
Locus Biosciences
(2015, United States, $32.3M)
Symbiomix Therapeutics
(2012, United States, $66.5M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

23. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
D3 Bio (2018, China)
$200M - Series A - Nov 2020
Annexon (2011, United States)
$102M - Series D - Jul 2020
Remegen (2008, China)
$100M - PE - Mar 2020
Q32 Bio (2018, United States)
$60.0M - Series B - Oct 2020
CatalYm (2016, Germany)
$59.3M - Series B - Nov 2020
GenFleet Therapeutics (2017, China)
$58.0M - Series B - Mar 2020
Q32 Bio (2018, United States)
$46.0M - Series A - May 2020
View all 15 Funding Rounds on Tracxn Platform
Immunology > Drugs > Autoimmune
Diseases
15
23
Back to index
Immunology (RedHill Biopharma)
(# Cos: 744 | $16.6B)
Drugs (DBV Technologies)
(# Cos: 620 | $15.8B)
Autoimmune Diseases (Moderna)
(# Cos: 72 | $4.8B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$606M (▲649%)
15(▲150%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
2
$4.8B
47
9
72
11
Moderna
(2010, United States, $2.8B)
X-37
(2019, United States, $14.5M)
Immutep
(2002, France)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

24. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Biologics based Drug Discovery
16
24
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$512M (▼19.8%)
23(▲15%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
13
$2.0B
128
9
214
17
Biotech R&D (Illumina)
(# Cos: 10357 | $53.7B)
Research Applications (Horizon Discovery)
(# Cos: 3784 | $31.4B)
Biopharma Research (MannKind Corp)
(# Cos: 1337 | $10.1B)
Drug Discovery (Relay Therapeutics)
(# Cos: 555 | $5.2B)
Biologics (GigaGen)
(# Cos: 214 | $2.0B)
GigaGen
(2011, United States, $36.1M)
Vividion Therapeutics
(2016, United States, $136M)
Dewpoint Therapeutics
(2018, United States, $137M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Ruike (2019, China)
$100M - Series B - Dec 2020
MOMA Therapeu.. (2020, United States)
$86.0M - Series A - Apr 2020
Remix Therape.. (2019, United States)
$81.0M - Series A - Dec 2020
Dewpoint Ther.. (2018, United States)
$77.1M - Series B - Sep 2020
Seraxis (2013, United States)
$40.0M - Series C - Feb 2021
Mana Therapeu.. (2017, United States)
$35.0M - Series A - Jan 2021
Nanjing Wei Li Zhi Bo.. (2014, China)
$29.8M - Series C - Oct 2020
View all 23 Funding Rounds on Tracxn Platform

25. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Infectious Diseases > Drugs > Bacterial > Drug
Resistant Infections
17
25
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$504M (▲180%)
17(▼32%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
22
$3.5B
155
23
203
20
Infectious Diseases (Oxford Immunotec)
(# Cos: 1690 | $23.1B)
Drugs (Moderna)
(# Cos: 950 | $18.9B)
Bacterial (Locus Biosciences)
(# Cos: 320 | $5.3B)
Drug Resistant Infections (Paratek
Pharma)
(# Cos: 203 | $3.5B)
Paratek Pharma
(1996, United States, $96.5M)
Locus Biosciences
(2015, United States, $32.3M)
Bioversys
(2008, Switzerland, $28.4M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Everest Medic.. (2017, United States)
$260M - Series C - Jun 2020
MicuRx Pharma.. (2007, United States)
$107M - Series E - Dec 2020
Everest Medic.. (2017, United States)
$50.0M - Series C - Mar 2020
Vedanta Biosc.. (2010, United States)
$25.0M - Series D - Jan 2021
Bioversys (2008, Switzerland)
$21.0M - Series B - Sep 2020
Pattern Biosc.. (2016, United States)
$9.0M - Series B - Jul 2020
Bugworks Research (2014, India)
$7.5M - Series A - Apr 2020
View all 17 Funding Rounds on Tracxn Platform

26. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Proteomic Based Diagnostic Tests
18
26
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$478M (▲758%)
8(▲14.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
5
$1.2B
45
4
88
7
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $41.1B)
Diagnostic Assays and Systems (MyHeritage)
(# Cos: 1619 | $19.2B)
In vitro Diagnostics (Illumina)
(# Cos: 1599 | $19.2B)
Protein-based (Oxford Immunotec)
(# Cos: 364 | $2.8B)
Proteomics (Somalogic)
(# Cos: 88 | $1.2B)
Somalogic
(1999, United States, $664M)
IsoPlexis
(2012, United States, $186M)
20/20 Gene Systems
(2000, United States, $8.3M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Somalogic (1999, United States)
$212M - Series E - Dec 2020
Somalogic (1999, United States)
$121M - Series E - Nov 2020
IsoPlexis (2012, United States)
$92.5M - Series D - Jan 2021
Sera Prognost.. (2008, United States)
$51.8M - Series D - Feb 2020
OncoNano Medi.. (2014, United States)
$21.5M - Series A - Oct 2020
Reccan Diagnostics (2015, Sweden)
$15.0M - Series B - Mar 2020
Mursla (2017, United Kingdom)
$547K - Seed - Sep 2020
View all 8 Funding Rounds on Tracxn Platform

27. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Gene Therapy > Diversified
19
27
Back to index
Gene Therapy (Moderna)
(# Cos: 350 | $13.7B)
Diversified (Akouos)
(# Cos: 27 | $629M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$469M (▲6246%)
10(▲233%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
-
$629M
17
1
27
6
Akouos
(2016, United States, $163M)
Senti Biosciences
(2016, United States, $158M)
Procarta Biosystems
(2007, United Kingdom, $4.2M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
AAVANTIBio (2017, United States)
$107M - Series A - Oct 2020
Akouos (2016, United States)
$105M - Series B - Mar 2020
Senti Bioscie.. (2016, United States)
$105M - Series B - Jan 2021
Atsena Therap.. (2020, United States)
$55.0M - Series A - Dec 2020
Ixaka (2009, United Kingdom)
$54.3M - Series C - Jan 2021
Spotlight The.. (2017, United States)
$30.0M - Series A - Nov 2020
Atsena Therap.. (2020, United States)
$8.5M - Series A - Apr 2020
View all 10 Funding Rounds on Tracxn Platform

28. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Beijing Mabworks Biot.. (2003, China)
$160M - Series C - Apr 2020
Olena Pharma (2007, United States)
$87.4M - Series C - Oct 2020
Olema Oncology (2007, United States)
$85.0M - Series C - Oct 2020
Olema Oncology (2007, United States)
$54.0M - Series B - Jul 2020
Olena Pharma (2007, United States)
$53.9M - Series B - Jun 2020
Shorla Pharma (2017, Ireland)
$8.3M - Series A - Jun 2020
Oncology > Drugs > Breast Cancer
20
28
Back to index
Oncology (Adaptive Biotechnologies)
(# Cos: 3963 | $79.7B)
Drugs (BioNTech)
(# Cos: 2543 | $61.1B)
Breast Cancer (Daré Bioscience)
(# Cos: 17 | $659M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$449M (▲7667%)
6(▲200%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
-
$659M
12
6
17
5
Daré Bioscience
(2015, United States)
Olena Pharma
(2007, United States, $147M)
Olema Oncology
(2007, United States, $139M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

29. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
At-Home Preventive Genetic Test Kits
21
29
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$430M (▲86.8%)
6(▼33.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$1.1B
44
1
179
8
Genomics (Illumina)
(# Cos: 6712 | $69.7B)
Applied Genomics (Adaptive Biotechnologies)
(# Cos: 3504 | $44.0B)
Consumer Genomics (MyHeritage)
(# Cos: 748 | $3.2B)
Proactive Healthcare (Color)
(# Cos: 179 | $1.1B)
Color
(2013, United States, $391M)
Everly Wellness
(2015, United States, $305M)
Viome
(2016, United States, $72.1M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Everly Wellness (2015, United States)
$175M - Series D - Dec 2020
Color (2013, United States)
$167M - Series D - Jan 2021
Everly Wellness (2015, United States)
$75.0M - Series D - Jan 2021
Variant Bio (2018, United States)
$6.1M - Series A - Aug 2020
GenoPalate (2016, United States)
$4.0M - Series A - Dec 2020
Viome (2016, United States)
$3.0M - Series B - Feb 2021

30. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Somalogic (1999, United States)
$212M - Series E - Dec 2020
Somalogic (1999, United States)
$121M - Series E - Nov 2020
Nautilus Biot.. (2016, United States)
$76.1M - Series B - May 2020
Newomics (2011, United States)
$7.9M - Series B - Oct 2020
ProteoWise (2018, United States)
$6.3M - Series A - Mar 2020
Mursla (2017, United Kingdom)
$547K - Seed - Sep 2020
nplex biosciences (2018)
$125K - Seed - Jul 2020
View all 9 Funding Rounds on Tracxn Platform
Biotech R&D > Research Applications >
Proteomics
22
30
Back to index
Biotech R&D (Illumina)
(# Cos: 10357 | $53.7B)
Research Applications (Horizon Discovery)
(# Cos: 3784 | $31.4B)
Proteomics (ProteinSimple)
(# Cos: 75 | $1.2B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$424M (▲681%)
9(▲125%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$1.2B
40
1
75
6
ProteinSimple
(2004, United States, $94.3M)
Biognosys
(2008, Switzerland, $9.1M)
Somalogic
(1999, United States, $664M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

31. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Orca Bio (2016, United States)
$192M - Series D - Jul 2020
Monte Rosa Th.. (2020, United States)
$96.0M - Series B - Sep 2020
Priothera (2020, Ireland)
$35.5M - Series A - Oct 2020
Monte Rosa Th.. (2020, United States)
$32.5M - Series A - May 2020
Auron Therape.. (2018, United States)
$15.4M - Seed - Dec 2020
MaaT Pharma (2014, France)
$8.8M - Series B - Dec 2020
ONK Therapeutics (2015, Ireland)
$8.0M - Series A - Oct 2020
View all 8 Funding Rounds on Tracxn Platform
Hematologic Cancer Drugs
23
31
Back to index
Oncology (Adaptive Biotechnologies)
(# Cos: 3963 | $79.7B)
Drugs (BioNTech)
(# Cos: 2543 | $61.1B)
Blood Cancer (Kiadis Pharma)
(# Cos: 79 | $2.7B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$390M (▲52.8%)
8(▼20%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$2.7B
57
18
79
8
Kiadis Pharma
(1997, Netherlands, $33.0M)
Syros Pharmaceuticals
(2012, United States, $124M)
ASLAN Pharmaceuticals
(2010, Singapore, $100M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

32. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Precision Medicine Software
24
32
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$386M (▲506%)
6(▲50%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$717M
15
1
24
4
Diagnostics (by Technology) (Illumina)
(# Cos: 5484 | $41.1B)
Diagnostic Software (PierianDx)
(# Cos: 629 | $4.4B)
Bioinformatics (Quest Diagnostics)
(# Cos: 110 | $1.3B)
Precision Medicine (N-of-One)
(# Cos: 58 | $801M)
Therapy Selection (Syapse)
(# Cos: 24 | $717M)
Syapse
(2008, United States, $188M)
N-of-One
(2008, United States, $17.8M)
Turbine
(2015, Hungary, $11.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
3DMed (2010, China)
$224M - Series D - Oct 2020
Syapse (2008, United States)
$68.0M - Series E - Feb 2021
NovellusDx (2011, Israel)
$57.0M - Series C - Sep 2020
Syapse (2008, United States)
$30.0M - Series E - May 2020
Turbine (2015, Hungary)
$6.8M - Seed - Jan 2021
3DMed (2010, China)
Undisclosed - Series C - Oct 2020

33. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Biotech R&D > Research Applications > Genomics > Genome
Engineering > Gene Editing
25
33
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$371M (▲169%)
13(▲30%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
4
$1.0B
44
2
63
11
Biotech R&D (Illumina)
(# Cos: 10357 | $53.7B)
Research Applications (Ginkgo Bioworks)
(# Cos: 3784 | $31.4B)
Genomics (Bionano Genomics)
(# Cos: 217 | $2.6B)
Genome Engineering (Mammoth)
(# Cos: 118 | $2.0B)
Gene Editing (Horizon Discovery)
(# Cos: 63 | $1.0B)
Horizon Discovery
(2007, United Kingdom, $46.3M)
Mammoth
(2017, United States, $75.5M)
Cibus
(2001, United States, $181M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Tessera Thera.. (2018, United States)
$230M - Series B - Jan 2021
EdiGene (2015, China)
$67.0M - Series B - Oct 2020
Tropic Biosc.. (2016, United Kingdom)
$28.5M - Series B - Jun 2020
Scribe Therap.. (2018, United States)
$20.0M - Series A - Oct 2020
Watchmaker Ge.. (2018, United States)
$8.3M - Series A - Dec 2020
ADARx Pharmac.. (2019, United States)
$6.0M - Series A - Nov 2020
ADARx Pharmac.. (2019, United States)
$5.0M - Series A - Aug 2020
View all 13 Funding Rounds on Tracxn Platform

34. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Heart Failure Therapy Devices
26
34
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$366M (▲103%)
16(▲33.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
15
$2.2B
85
7
98
17
Cardiac and Vascular Disorders (Moderna)
(# Cos: 2206 | $28.3B)
Medical Devices (Withings)
(# Cos: 1758 | $18.1B)
Therapeutic Devices (Edwards
Lifesciences)
(# Cos: 956 | $13.9B)
Congestive Heart Failure (Sequena
Medical)
(# Cos: 98 | $2.2B)
Sequena Medical
(2006, Switzerland, $35.5M)
Abiomed
(1981, United States)
SynCardia
(2001, United States, $72.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Element Science (2013, United States)
$146M - Series C - Mar 2020
Impulse Dynamics (1996, Germany)
$60.0M - Series D - Jan 2021
CorWave (2011, France)
$43.0M - Series C - Jan 2021
V-Wave (2009, Israel)
$28.0M - Series C - Sep 2020
Cardionomic (2012, United States)
$15.8M - Series B - Feb 2020
Reprieve Card.. (2018, United States)
$15.0M - Series B - Aug 2020
CardioPolymers (2003, United States)
$13.6M - Series B - Jul 2020
View all 16 Funding Rounds on Tracxn Platform

35. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Biotech R&D > Research Applications > Translational
Research > Biomarkers > Agriculture
27
35
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$360M (▲106%)
1( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$1.1B
5
-
7
1
Biotech R&D (Illumina)
(# Cos: 10357 | $53.7B)
Research Applications (Horizon Discovery)
(# Cos: 3784 | $31.4B)
Translational Research (NanoString)
(# Cos: 210 | $3.2B)
Biomarkers (Human Longevity)
(# Cos: 121 | $2.4B)
Agriculture (Indigo)
(# Cos: 7 | $1.1B)
Indigo
(2016, United States, $1.1B)
Meta Helix Life Sciences
(2000, India, $8.7M)
Probiotic Holdings
(2004, United States, $1.1M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Indigo (2016, United States)
$360M - Series F - Jun 2020

36. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Immunotherapy > Oncolytic Virus
28
36
Back to index
Immunotherapy (Alexion)
(# Cos: 1835 | $48.2B)
Oncolytic Virus (Transgene)
(# Cos: 63 | $1.6B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$344M (▲57.1%)
10( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
7
$1.6B
52
6
63
8
Transgene
(1979, France, $186M)
Replimune
(2015, United Kingdom, $87.0M)
Oncorus
(2016, United States, $141M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Adlai Nortye (2014, China)
$100M - Series C - Aug 2020
Wuhan Binhui Biotechn.. (2010, China)
$92.9M - Series B - Feb 2021
IconOVir (2020, United States)
$77.0M - Series A - Jan 2021
Immvira (2015, China)
$58.0M - Series B - Jun 2020
Immvira (2015, China)
$10.0M - Series B - Sep 2020
TILT Biotherapeutics (2013, Finland)
$5.1M - Series A - Jun 2020
Seneca Therap.. (2015, United States)
$820K - Seed - Mar 2020
View all 10 Funding Rounds on Tracxn Platform

37. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Robotic Surgery Instruments
29
37
Back to index
Surgical Instruments (TransEnterix)
(# Cos: 597 | $5.0B)
Robotic Surgery (Intuitive)
(# Cos: 133 | $3.0B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$337M (▼14%)
13(▼18.8%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
19
$3.0B
87
12
133
18
Intuitive
(1995, United States, $47.0M)
TransEnterix
(2006, United States, $96.2M)
CMR Surgical
(2014, United Kingdom, $427M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Edge Medical Robotics (2017, China)
$92.6M - Series B - Jan 2021
PROCEPT BioRo.. (2009, United States)
$77.0M - Series C - Aug 2020
Remebot (2015, China)
$65.7M - Series D - Dec 2020
Robocath (2009, France)
$43.4M - Series C - Apr 2020
Activ Surgical (2017, United States)
$15.0M - Series B - Jun 2020
Edge Medical Robotics (2017, China)
$14.1M - Series A - Apr 2020
Memic Surgery (2013, Israel)
$11.3M - Series A - Dec 2020
View all 13 Funding Rounds on Tracxn Platform

38. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Neurogene (2001, United States)
$115M - Series B - Dec 2020
Autobahn Ther.. (2019, United States)
$76.0M - Series B - Jun 2020
Longboard Pha.. (2020, United States)
$56.0M - Series C - Oct 2020
QurAlis (2016, United States)
$42.0M - Series A - May 2020
Alcyone Life .. (2010, United States)
$17.6M - Series C - Sep 2020
Polyneuron (2014, Switzerland)
$15.4M - Series A - Sep 2020
Retrotope (2008, United States)
$13.3M - Series D - Jan 2021
View all 8 Funding Rounds on Tracxn Platform
Rare Neurological Disease Drugs
30
38
Back to index
Rare Diseases (Moderna)
(# Cos: 463 | $18.9B)
Drugs (Alexion)
(# Cos: 448 | $18.8B)
CNS (Engage Therapeutics)
(# Cos: 44 | $1.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$336M (▲94.4%)
8(▼20%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
6
$1.3B
34
10
44
6
Engage Therapeutics
(2017, United States, $30.6M)
Polyneuron
(2014, Switzerland, $40.2M)
MindMed
(2019, Canada)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

39. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Goldfinch (2016, United States)
$100M - Series B - Jun 2020
Pharvaris (2015, Netherlands)
$80.0M - Series C - Nov 2020
Dynacure (2016, France)
$54.8M - Series C - Apr 2020
Palladio Bios.. (2016, United States)
$28.0M - Series B - Sep 2020
Attralus (2019, United States)
$25.0M - Series A - Sep 2020
ILIAS Biologics (2015, South Korea)
$20.6M - Series B - Sep 2020
NFlection The.. (2017, United States)
$20.0M - Series B - Apr 2020
View all 19 Funding Rounds on Tracxn Platform
Rare Metabolic Disorder Drugs
31
39
Back to index
Rare Diseases (CureVac)
(# Cos: 463 | $18.9B)
Drugs (Alexion)
(# Cos: 448 | $18.8B)
Metabolic Disorders (Moderna)
(# Cos: 156 | $7.0B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$328M (▼26.1%)
19( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
27
$7.0B
121
28
156
15
Moderna
(2010, United States, $2.8B)
Catabasis Pharmaceutic..
(2008, United States, $116M)
Horizon Therapeutics
(2008, Ireland, $61.8M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

40. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Orca Bio (2016, United States)
$192M - Series D - Jul 2020
Talaris (2019, United States)
$115M - Series B - Oct 2020
Polyneuron (2014, Switzerland)
$15.4M - Series A - Sep 2020
Immunology > Drugs > GvHD
32
40
Back to index
Immunology (DBV Technologies)
(# Cos: 744 | $16.6B)
Drugs (Moderna)
(# Cos: 620 | $15.8B)
GvHD (GigaGen)
(# Cos: 14 | $584M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$322M (▲163%)
3(▲50%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
2
$584M
11
1
14
6
GigaGen
(2011, United States, $36.1M)
Polyneuron
(2014, Switzerland, $40.2M)
Orca Bio
(2016, United States, $192M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

41. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Dyne Therapeu.. (2018, United States)
$116M - Series B - Aug 2020
AAVANTIBio (2017, United States)
$107M - Series A - Oct 2020
Keros Therape.. (2016, United States)
$56.0M - Series C - Mar 2020
Knopp Bioscie.. (2005, United States)
$12.7M - Series D - Mar 2020
Knopp Bioscie.. (2005, United States)
$12.6M - Series D - Oct 2020
Versameb (2017, Switzerland)
$6.4M - Seed - Jul 2020
ARTHEx (2018, Spain)
$4.9M - Series A - Jul 2020
View all 11 Funding Rounds on Tracxn Platform
Neurology > Drugs > Neuromuscular
33
41
Back to index
Neurology (Kernel)
(# Cos: 2170 | $24.9B)
Drugs (Biogen)
(# Cos: 1169 | $18.9B)
Neuromuscular (Scholar Rock)
(# Cos: 35 | $1.1B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$319M (▲57.5%)
11(▲37.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
6
$1.1B
21
3
35
9
Scholar Rock
(2012, United States, $103M)
Dyne Therapeutics
(2018, United States, $166M)
Keros Therapeutics
(2016, United States, $90.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

42. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Diabetes Drugs
34
42
Back to index
Diabetes (Livongo)
(# Cos: 788 | $8.1B)
Drugs (Pendulum)
(# Cos: 216 | $4.2B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$319M (▼32.4%)
19( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
17
$4.2B
149
23
216
19
Pendulum
(2012, United States, $57.0M)
Rezolute
(2012, United States)
Xeris Pharma
(2005, United States, $155M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Kriya Therape.. (2012, United States)
$85.6M - Series A - May 2020
Carmot Therap.. (2010, United States)
$47.0M - Series C - Sep 2020
Enthera (2016, Italy)
$32.8M - Series A - Jul 2020
ViaCyte (1999, United States)
$32.6M - Series D - Apr 2020
Regenacy (2016, United States)
$30.0M - Series A - Mar 2020
Glyscend (2014, United States)
$20.5M - Series A - Jun 2020
Elevian (2017, United States)
$15.3M - Series A - Jul 2020
View all 19 Funding Rounds on Tracxn Platform

43. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Cell Therapy > Diversified
35
43
Back to index
Cell Therapy (Kite Pharma)
(# Cos: 539 | $13.2B)
Diversified (Athira Pharma)
(# Cos: 69 | $910M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$315M (▲229%)
8(▲167%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
7
$910M
51
9
69
4
Athira Pharma
(2011, United States, $109M)
Tenaya Therapeutics
(2016, United States, $142M)
Orca Bio
(2016, United States, $192M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Orca Bio (2016, United States)
$192M - Series D - Jul 2020
Athira Pharma (2011, United States)
$89.0M - Series B - Jun 2020
LUCA Science (2018, Japan)
$9.8M - Series A - Sep 2020
ExocoBio (2017, South Korea)
$9.3M - Series C - Aug 2020
Aegle Therape.. (2013, United States)
$6.5M - Series A - Jul 2020
TikoMed (2002, Sweden)
$5.6M - Series A - Mar 2020
Oisín Biotech.. (2014, United States)
$2.1M - Seed - Jun 2020
View all 8 Funding Rounds on Tracxn Platform

44. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
LianBio (1999, China)
$310M - Series D - Oct 2020
Cardiac and Vascular Disorders > Drugs >
Valvular Disorders
36
44
Back to index
Cardiac and Vascular Disorders (Withings)
(# Cos: 2206 | $28.3B)
Drugs (Moderna)
(# Cos: 300 | $9.4B)
Valvular Disorders (LianBio)
(# Cos: 2 | $310M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$310M ( -- )
1( -- )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
-
$310M
2
-
2
1
LianBio
(1999, China, $310M)
Spark Biopharma
(2016, South Korea)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

45. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Pivot Bio (2010, United States)
$100M - Series C - May 2020
Ginkgo Bioworks (2009, United States)
$70.0M - Series E - May 2020
LifeMine Ther.. (2016, United States)
$50.0M - Series B - Jan 2021
Checkerspot (2016, United States)
$36.0M - Series B - May 2020
Evonetix (2015, United Kingdom)
$30.0M - Series B - Mar 2020
Prokarium (2012, United Kingdom)
$21.0M - Series B - Oct 2020
Trident Biosc.. (2019, United States)
$150K - Seed - Aug 2020
Synthetic Biology
37
45
Back to index
Genomics (Illumina)
(# Cos: 6712 | $69.7B)
Applied Genomics (MyHeritage)
(# Cos: 3504 | $44.0B)
Synthetic Biology (Ginkgo Bioworks)
(# Cos: 60 | $3.8B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$307M (▼23%)
7(▲16.7%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
7
$3.8B
46
4
60
12
Ginkgo Bioworks
(2009, United States, $796M)
Amyris
(2003, United States, $487M)
Synlogic Therapeutics
(2013, United States, $34.4M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

46. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Diagnostics (by Technology) > Diagnostic Assays and Systems > In vitro
Diagnostics > Cell or Tissue-based > Liquid Biopsy > Circulating Tumor
Cells
38
46
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$284M (▲144%)
3(▼40%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
4
$641M
22
3
35
3
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $41.1B)
Diagnostic Assays and Systems (MyHeritage)
(# Cos: 1619 | $19.2B)
In vitro Diagnostics (Illumina)
(# Cos: 1599 | $19.2B)
Cell or Tissue-based (Epic Sciences)
(# Cos: 147 | $1.9B)
Liquid Biopsy (Exosome Diagnostics)
(# Cos: 51 | $1.0B)
Circulating Tumor Cells (Thrive
Earlier Detection)
(# Cos: 35 | $641M)
Thrive Earlier Detection
(2019, United States, $367M)
Epic Sciences
(2008, United States, $138M)
ApoCell
(2004, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Thrive Earlie.. (2019, United States)
$257M - Series B - Jul 2020
Naveris (2017, United States)
$17.0M - Series B - Mar 2020
Polaris Biology (2016, China)
$9.9M - Series B - Jun 2020

47. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Genechem (2002, China)
$56.4M - Series C - Apr 2020
MedGenome (2013, India)
$55.0M - Series D - Apr 2020
Cyagen (2005, United States)
$40.5M - Series B - Feb 2020
Clear Labs (2014, United States)
$39.5M - Series B - May 2020
Health Gene Technolog.. (2011, China)
$33.4M - Series A - Dec 2020
Beikang Medical (2010, China)
$21.1M - Series C - May 2020
Trace Genomics (2015, United States)
$17.2M - Series B - Jul 2020
View all 13 Funding Rounds on Tracxn Platform
Genomics Research Services
39
47
Back to index
Biotech R&D (Illumina)
(# Cos: 10357 | $53.7B)
Services and Enablers (Atomwise)
(# Cos: 1417 | $2.7B)
Genomics (Ancestry)
(# Cos: 485 | $1.2B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$284M (▲8155%)
13(▲62.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
38
$1.2B
135
12
485
13
Ancestry
(1996, United States, $146M)
Personalis
(2011, United States, $87.3M)
MedGenome
(2013, India, $151M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

48. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
iTeos Therape.. (2011, United States)
$125M - Series B - Apr 2020
Annexon (2011, United States)
$102M - Series D - Jul 2020
Inxmed (2018, China)
$19.0M - Series A - Sep 2020
Auron Therape.. (2018, United States)
$15.4M - Seed - Dec 2020
Phost'In (2013, France)
$11.1M - Series A - Apr 2020
Athena Therap.. (2018, United States)
Undisclosed - Seed - Dec 2020
Small Molecules Targeting Immunosuppressive
Pathway Inhibitors
40
48
Back to index
Immunotherapy (Alexion)
(# Cos: 1835 | $48.2B)
Small Molecule (Syndax)
(# Cos: 165 | $3.8B)
Immunosuppressive Pathway Inhibitors
(iTeos Therapeutics)
(# Cos: 54 | $1.5B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$273M (▲115%)
6(▲100%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
5
$1.5B
41
10
54
5
iTeos Therapeutics
(2011, United States, $204M)
Syndax
(2005, United States, $195M)
NewLink Genetics Corpo..
(1999, United States, $20.5M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

49. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Diagnostics (by Technology) > Diagnostic Assays and Systems
> In vitro Diagnostics > Multi-omic Assays > Liquid Biopsy
41
49
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$270M (▲38.3%)
2(▼60%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$790M
9
4
14
2
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $41.1B)
Diagnostic Assays and Systems (MyHeritage)
(# Cos: 1619 | $19.2B)
In vitro Diagnostics (Illumina)
(# Cos: 1599 | $19.2B)
Multi-omic Assays (Biodesix)
(# Cos: 32 | $1.1B)
Liquid Biopsy (Freenome)
(# Cos: 14 | $790M)
Freenome
(2014, United States, $508M)
Biodesix
(2005, United States, $190M)
Biocept
(1993, United States, $53.1M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Freenome (2014, United States)
$270M - Series C - Aug 2020
Scipher Medic.. (2014, United States)
Undisclosed - Series B - Feb 2020

50. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Genetic Engineering Technologies
42
50
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$265M (▲161%)
8(▲100%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
3
$838M
37
2
62
7
Genomics (Illumina)
(# Cos: 6712 | $69.7B)
Enabling Technologies (10X Genomics)
(# Cos: 1535 | $16.0B)
Technology Platforms (Horizon
Discovery)
(# Cos: 338 | $8.3B)
Genetic Engineering (Senti
Biosciences)
(# Cos: 62 | $838M)
Senti Biosciences
(2016, United States, $158M)
Tmunity Therapeutics
(2015, United States, $231M)
GreenLight Biosciences
(2009, United States, $215M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Senti Bioscie.. (2016, United States)
$105M - Series B - Jan 2021
GreenLight Bi.. (2009, United States)
$102M - Series D - Jun 2020
GreenLight Bi.. (2009, United States)
$17.0M - Series D - May 2020
LabGenius (2012, United Kingdom)
$15.0M - Series A - Oct 2020
Geninus (2018, South Korea)
$13.3M - Series B - Aug 2020
ADARx Pharmac.. (2019, United States)
$6.0M - Series A - Nov 2020
ADARx Pharmac.. (2019, United States)
$5.0M - Series A - Aug 2020
View all 8 Funding Rounds on Tracxn Platform

51. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Frontier Medi.. (2018, United States)
$67.0M - Series A - Nov 2020
HotSpot Thera.. (2017, United States)
$65.0M - Series B - May 2020
Exscientia (2012, United Kingdom)
$60.0M - Series C - May 2020
Accutar Biote.. (2015, United States)
$28.5M - Series C - Jan 2021
Accutar Biote.. (2015, United States)
$20.0M - Series B - Sep 2020
NTxBio (2016, United States)
$13.0M - Series A - Feb 2020
PostEra (2019, United Kingdom)
$150K - Seed - Mar 2020
View all 8 Funding Rounds on Tracxn Platform
Biotech R&D > Research Software >
Chemoinformatics
43
51
Back to index
Biotech R&D (Illumina)
(# Cos: 10357 | $53.7B)
Research Software (Seer)
(# Cos: 799 | $4.9B)
Chemoinformatics (HotSpot
Therapeutics)
(# Cos: 51 | $507M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$254M (▲562%)
8(▲14.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$507M
25
-
51
6
HotSpot Therapeutics
(2017, United States, $110M)
Oxford Drug Design
(2001, United Kingdom, $7.3M)
Exscientia
(2012, United Kingdom, $104M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

52. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Life Sciences Tech > Research & Development >
Image Analysis > Digital Pathology
44
52
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$252M (▲429%)
7(▲133%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$515M
25
-
74
6
Life Sciences Tech (Medidata)
(# Cos: 3282 | $14.6B)
Research & Development (Illumina)
(# Cos: 2538 | $11.7B)
Image Analysis (MEDIAN Technologies)
(# Cos: 164 | $853M)
Digital Pathology (PAIGE)
(# Cos: 74 | $515M)
PAIGE
(2018, United States, $241M)
Visiopharm
(2001, Denmark, $26.3M)
Proscia
(2014, United States, $35.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
PAIGE (2018, United States)
$100M - Series C - Jan 2021
PAIGE (2018, United States)
$71.0M - Series B - Jul 2020
Resolve Biosciences (2020, Germany)
$24.0M - Series A - Dec 2020
Proscia (2014, United States)
$23.0M - Series B - Nov 2020
Deepcell (2015, United States)
$20.0M - Series A - Dec 2020
Visiopharm (2001, Denmark)
$7.5M - Series B - Jul 2020
Deciphex (2017, Ireland)
$6.2M - Series A - Jul 2020

53. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Huayin Health (2009, China)
$85.0M - Series C - Apr 2020
OBiO Technology (2013, China)
$44.2M - Series C - Sep 2020
Cyagen (2005, United States)
$40.5M - Series B - Feb 2020
OBiO Technology (2013, China)
$28.5M - Series B - Jul 2020
Topgen (2012, China)
$17.1M - Series C - Jul 2020
Huayin Health (2009, China)
$15.3M - Series C - Dec 2020
OBiO Technology (2013, China)
$14.4M - Series B - Mar 2020
View all 9 Funding Rounds on Tracxn Platform
Genomics > Genomics Services > Full
Service
45
53
Back to index
Genomics (Illumina)
(# Cos: 6712 | $69.7B)
Genomics Services (OXGENE)
(# Cos: 771 | $2.2B)
Full Service (Personalis)
(# Cos: 282 | $1.2B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$249M (▲452%)
9(▲200%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
14
$1.2B
56
4
282
9
Personalis
(2011, United States, $87.3M)
OXGENE
(2011, United Kingdom, $22.0M)
LakePharma
(2009, United States, $30.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

54. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Pharmocogenomic Tests
46
54
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$249M (▲2205%)
5(▲66.7%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
10
$991M
41
5
93
7
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $41.1B)
Diagnostic Assays and Systems (Guardant Health)
(# Cos: 1619 | $19.2B)
In vitro Diagnostics (23andMe)
(# Cos: 1599 | $19.2B)
Nucleic Acid-based (Adaptive
Biotechnologies)
(# Cos: 879 | $12.8B)
Sequencing-based (MyHeritage)
(# Cos: 660 | $10.3B)
Genomics (Illumina)
(# Cos: 613 | $9.7B)
Pharmacogenomics
(Foundation Medicine)
(# Cos: 93 | $991M)
Foundation Medicine
(2010, United States, $96.5M)
Caris Life Sciences
(1996, United States, $235M)
Interleukin Genetics
(1986, United States, $33.6M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Caris Life Sc.. (1996, United States)
$235M - Unattributed - Oct 2020
Strata Oncology (2015, United States)
$5.0M - Series B - Nov 2020
Genomind (2009, United States)
$4.9M - Series C - Dec 2020
AltheaDx (2009, United States)
$3.7M - Series D - Dec 2020
Noscendo (2016, Germany)
Undisclosed - Series A - Mar 2020

55. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Spinal Therapy Devices
47
55
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$246M (▲447%)
18(▲80%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
61
$4.0B
182
21
343
14
Orthopedics (Horizon Therapeutics)
(# Cos: 2050 | $10.8B)
Medical Devices (NuVasive)
(# Cos: 1856 | $8.8B)
Therapies (Invacare)
(# Cos: 1540 | $8.0B)
Spinal Devices (Globus Medical)
(# Cos: 343 | $4.0B)
Globus Medical
(2003, United States, $110M)
Vertiflex
(2005, United States, $110M)
ATEC Spine
(1990, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Relievant Med.. (2004, United States)
$70.0M - Series F - Oct 2020
Spineart (2005, Switzerland)
$52.0M - Series B - Jun 2020
Centinel Spine (2008, United States)
$40.5M - Series C - Apr 2020
Viseon (2017, United States)
$29.4M - Series B - Feb 2020
Curiteva (2018, United States)
$20.5M - Series A - Dec 2020
WISE (2011, Italy)
$17.6M - Series C - Oct 2020
3Spine (2017, Cayman Islands)
$10.0M - Series A - Aug 2020
View all 18 Funding Rounds on Tracxn Platform

56. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Sirnaomics (2007, United States)
$105M - Series D - Oct 2020
Souzhou Ribo Life Sci.. (2007, China)
$66.2M - Series C - Apr 2020
Dynacure (2016, France)
$54.8M - Series C - Apr 2020
Ractigen (2015, China)
$17.1M - Series A - Feb 2021
DTx Pharma (2017, United States)
$200K - Series A - Jul 2020
siRNA based Gene Therapy Drugs
48
56
Back to index
Gene Therapy (MiRagen)
(# Cos: 350 | $13.7B)
RNA (Moderna)
(# Cos: 152 | $6.5B)
siRNA (Alnylam)
(# Cos: 68 | $1.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$243M (▲18.8%)
5(▼37.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$1.3B
49
12
68
7
Alnylam
(2002, United States, $17.0M)
Dicerna Pharmaceuticals
(2007, United States, $107M)
Silence Therapeutics
(1999, United Kingdom)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

57. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Gastroenterology > Drugs > Bowel Disorders >
Inflammatory Bowel Disorders
49
57
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$241M ( -- )
7( -- )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$424M
10
2
14
5
Gastroenterology (RedHill Biopharma)
(# Cos: 395 | $4.3B)
Drugs (Ironwood Pharma)
(# Cos: 158 | $2.5B)
Bowel Disorders (Pendulum)
(# Cos: 22 | $603M)
Inflammatory Bowel Disorders
(Enterome)
(# Cos: 14 | $424M)
Enterome
(2011, France, $130M)
Aclaris Therapeutics
(2012, United States, $82.0M)
Prometheus Biosciences
(2016, United States, $130M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Prometheus Bi.. (2016, United States)
$130M - Series D - Nov 2020
Enterome (2011, France)
$52.3M - Series E - Jun 2020
Enthera (2016, Italy)
$32.8M - Series A - Jul 2020
Rodeo Therape.. (2017, United States)
$8.9M - Series A - Apr 2020
Enthera (2016, Italy)
$8.5M - Series A - Jan 2021
Qu Biologics (2007, Canada)
$8.0M - Series B - Dec 2020
MicrobiomX (2017, United States)
$505K - Seed - Jun 2020

58. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Annexon (2011, United States)
$102M - Series D - Jul 2020
Terns Pharmac.. (2017, United States)
$97.7M - Series C - Jan 2021
Forge Biologics (2020, United States)
$40.0M - Series A - Jul 2020
Rare Diseases > Drugs > Autoimmune
Diseases
50
58
Back to index
Rare Diseases (Moderna)
(# Cos: 463 | $18.9B)
Drugs (Alexion)
(# Cos: 448 | $18.8B)
Autoimmune Diseases (Terns
Pharmaceutical)
(# Cos: 12 | $1.4B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$240M ( -- )
3( -- )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
-
$1.4B
8
3
12
1
Terns Pharmaceutical
(2017, United States, $208M)
Annexon
(2011, United States, $256M)
Kiniksa Pharmaceuticals
(2015, United Kingdom, $320M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

59. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Recent funding rounds
Investment Trends
Most Active Investors
Top Funded Business Models
Explore more on Tracxn
All Tech Companies
US Tech Companies
Online Travel Companies
Companies using AI in Healthcare
Companies founded by Stanford GSB Alumni
Soonicorn club in Fintech
Analyst Picks in Israel Tech
Key News in FinTech
Events in Bay Area
Angel Investors in United States
Bluebox
Companies Investment Activity
Miscellaneous
Company Detail Page of DoorDash
Competitors of Freshworks
Cap Table for TransferWise
Financials for Ola
Employee Count for Revolut
Company Due Diligence Exits
Public Companies
Acquired Companies
Most Active Acquirers
Reports
Delhivery - Company Report
Novel Foods - Business Model Report
HRTech - Feed Report
FinTech - Top Business Models Report
US Tech - Top Business Models Report
US Tech - Monthly Report
59

60. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Explore other Reports on Tracxn
HRTech
InsurTech
Food Tech
Novel Foods
Blockchain Network
P2P Remittance
Business Model Reports
FinTech Europe
Consumer Digital SEA
HiTech US
Feed Geo Reports
Company Reports
Monthly Unicorn Report
Unicorn Reports
Transferwise
Coursera
BigBasket
Feed Reports Top Business Models in PA
FinTech
Enterprise Applications
Artificial Intelligence
Geo Monthly Reports
US Tech
Europe Tech
China Tech
Top Business Models in Geo
India Tech
Israel Tech
UK & Ireland Tech
60

61. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Any and all information either accessed from the website www.tracxn.com or having otherwise originated from Tracxn Technologies Private Limited including but not limited to the
information contained herein ("Data") is the sole property of Tracxn Technologies Private Limited (hereinafter "Tracxn"). You shall not recirculate, distribute, transmit, publish, or
sell the Data or any portion thereof in any form or by any means, either for commercial or non-commercial use, or permit any third party to use or distribute the Data or any
portion thereof; to any other party, except with the prior written consent of Tracxn. You may however incorporate insubstantial portions, extracts, abstracts or summaries from the
Data into analysis, presentations or tools for your customers or for your internal use, so long as Tracxn is clearly and visibly identified as the source of information.
For further information please refer to our Terms of Use at www.tracxn.com